Skip to content

Bioequivalence evaluation of two Sofobuvir tablets in healthy Chinese volunteers: A Single-dose, randomized, open-label, Fasting and fed study

Bioequivalence evaluation of two Sofobuvir tablets in healthy Chinese volunteers: A Single-dose, randomized, open-label, Fasting and fed study

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019750
Enrollment
Unknown
Registered
2018-11-26
Start date
2018-11-15
Completion date
Unknown
Last updated
2018-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCV

Interventions

Group 1:T-R-T-R
Group 2:R-T-R-T

Sponsors

The First Affiliated Hospital, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-45, healthy male and female subjects; 2. Male subjects with weight =50kg, female subjects with weight =45kg; body mass index [BMI=weight (kg)/height (m)2] within the range of 19-26kg/m2; 3. subjects in healthy condition, without significant clinical symptoms or abnormal laborary test results of clinical significance; 4. subjects have a fair understanding of the purpose, property, progress and adverse event that may happen, and volunteer to sign the ICF; 5. Subject are able to proceed a smooth Communication with researchers, and a good compliance to the requirements of the study. subject are willing to say at Phase I study wards according to rules.

Exclusion criteria

Exclusion criteria: 1. subject cannot tolarate veinpunture; 2. Subject allergic to the study drug or its ingredients; subject has history of allergy or belongs to allergic constitution; 3. Subject has/had any history of serious disease, including but not limited to digestive, cardiovascular, respiratory, urinary, musculoskeletal, endorine, nervous, hemotologic, immune system or metabolic disorder; 4. Subject had surgery that may impact gastrointestinal tract; 5. labotory test: hemotology, urinalysis, blood biochemistry, chest X-ray, 12-lead ECG. Any of the above items is abnormal and determined clinical significant by researchers; 6. One of HbsAg, HCV antibody, HIV antibody, syphilis turn out to be positive; 7. Female subjects under pregenancy, lactation, or cannot take conspective measures; 8. Male subjects cannot take conspective measures or his parter plans to get pregnancy in 6 months; 9. subject took over 5 cigarettes every day in the past 12 months, or cannot quit smoking during the study; subject drank frequently in the past 6 months, namely 14 unit alcohol every week( 1 unit =360ml beer with 5% alcohol, 45ml liquor with 40% alcohol, 150 ml wine with 12% alcohol); 10. Subjects has history of abusement of prescription/illegal drugs; 11. subject had vaccination, any prescription or Chinese herbal medicine 4 weeks prior to first administration; subject took any OTC, food suppliment(including vitamin) 2 weeks prior to first administration; 12. Urine tests of drug abuse, alchol turn to be positive; 13. Subjects donated blood or experience an acute blood loss(over 400ml) 2 week prior to screening; 14. subject participated in other clinical trial 3 month before screening; 15. subject refuses to stop any food or revee with methylxanthine, such as caffeine (coffee, tea, coke, choclate) from 2 days before to the end of the study; 16. subject refused to stop any food or reverage with grapefruit from 7 days before to the end of the study; 16. subject has a big change in his/her diet or exercise; 17. subject insuitable to the study according to researchers.

Design outcomes

Primary

MeasureTime frame
Cmax;AUC;

Contacts

Public ContactShentu Jianzhong

The First Affiliated Hospital, Zhejiang University

stjz@zju.edu.cn+86 0571-87236560

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026